MACBEATH GAVIN (Chief Scientific Officer) purchased 11.2% of their position (5K shares) of TSCAN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $31.1K — a moderate purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 9/22/2021ACC: 0000899243-21-037147
Officer· Chief Scientific Officer
Since Jul 2021
+5K
Net shares
Net buyer
$31.1K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
5K acquired
Non-Derivative Transactions2
Voting Common Stock
Direct
Shares
+4.94K
Price / share
$6.22
Trade value
$30.74K
% of position
11.0%
9/20/2021
44.77K→49.71K
Voting Common Stock
Direct
Shares
+57.00
Price / share
$6.19
Trade value
$352.72
% of position
0.1%
9/21/2021
49.71K→49.77K
Total
Net shares
+5K
Net value
$31.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Voting Common Stock Direct | 9/20/2021 | P · Purchase | +4.94K | $6.22 | $30.74K | 11.0% | 44.77K | 49.71K |
| Voting Common Stock Direct | 9/21/2021 | P · Purchase | +57.00 | $6.19 | $352.72 | 0.1% | 49.71K | 49.77K |
| Total | +5K | $31.10K | ||||||
Derivative Transactions0
No derivative transactions reported